Do you manage patients with schizophrenia?
Learn how you can get involved to support a nearby study that is enrolling qualified patients with moderate-to-severe negative schizophrenia symptoms
About the Research Study
Novartis Pharmaceuticals Corporation is currently conducting a phase 3 clinical research program called SIRIUS-SLE, which is looking to enroll approximately 700 participants globally. The research program is evaluating the efficacy, safety, and tolerability of the investigational drug, ianalumab, on top of standard-of-care therapy in patients with active SLE.
The investigational drug, ianalumab, is thought to have a dual action – it may deplete B cells while also potentially blocking B-cell activating factor (BAFF) activity. In this way, it’s hoped that the investigational drug will limit the damaging effects of B-cell activity that cause the symptoms of SLE. All participants in the clinical research program will remain on their standard of care therapy for SLE alongside their assigned trial treatment.
For more information about the clinical research program, visit the following websites:
- https://www.novartis.com/us-en/clinicaltrials/immunology/SLE/NCT05639114-NCT05624749
- https://clinicaltrials.gov/study/NCT05639114
- https://clinicaltrials.gov/study/NCT05624749
How You Can Get Involved
As a health care provider (HCP) who manages patients with SLE, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the SIRIUS-SLE Clinical Research Program. Should you decide to participate, you would identify which of your patients meet the provided inclusion/exclusion criteria and discuss with them the opportunity to participate at the nearby study site. Patients will undergo formal study screening with the Principal Investigator to determine eligibility. Patients may be able to take part if they meet the following criteria*:
- Are 12 years of age or older
- Have been diagnosed with SLE for at least 6 months
- Are taking any of the following medications, either alone or in combination: corticosteroids, antimalarial treatment, methotrexate, azathioprine, mizoribine, or mycophenolate
- Weigh at least 77 lbs
*Patients will need to meet additional study criteria, which will be provided to you upon program training.
Compensation at fair market value will be provided to HCPs who participate and meet program requirements.

The Effectus Patient Identification and Consultation Program
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients throughout the screening process and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation.
Participation is completely voluntary, and you can opt out at any time. Background on the study, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session, for which you will be compensated.
Why Participate?
Despite an improvement in the overall SLE treatment landscape over several decades, more treatment options are needed to help reduce flare-ups and prevent disease progression with minimal side effects. That’s why the SIRIUS-SLE Clinical Research Program is being conducted. The aim is to find out how safe and effective an investigational drug is in treating SLE alongside standard of care therapy. Participation in the Effectus Patient Identification and Consultation Program provides an opportunity for you to contribute to this research and advancement of a potential treatment option for SLE.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.

The Effectus Patient Identification and Consultation Program
Contact Us
Montana Markell, Project Coordinator
Phone: 973-753-2430
Email: mmarkell@effectusctr.com